According to Zacks, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. “
Other analysts have also recently issued research reports about the stock. Leerink Swann cut shares of TESARO from an outperform rating to a market perform rating and set a $186.00 price objective for the company. in a research note on Friday, February 10th. They noted that the move was a valuation call. Cowen and Company set a $155.00 price objective on shares of TESARO and gave the company a hold rating in a research note on Saturday, February 25th. FBR & Co cut shares of TESARO from an outperform rating to a market perform rating and upped their price objective for the company from $151.00 to $202.00 in a research note on Thursday, February 16th. Wedbush reaffirmed an outperform rating and set a $139.00 price objective on shares of TESARO in a research note on Wednesday, December 21st. Finally, Robert W. Baird dropped their price objective on shares of TESARO from $182.00 to $165.00 and set a positive rating for the company in a research note on Wednesday, March 15th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. TESARO presently has an average rating of Buy and an average price target of $166.84.
Shares of TESARO (NASDAQ:TSRO) opened at 156.73 on Wednesday. The stock’s 50 day moving average is $172.85 and its 200 day moving average is $139.14. The company’s market cap is $8.40 billion. TESARO has a 1-year low of $36.68 and a 1-year high of $192.94.
WARNING: “Zacks Investment Research Downgrades TESARO Inc (TSRO) to Sell” was originally published by Mideast Time and is the property of of Mideast Time. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.mideasttime.com/zacks-investment-research-downgrades-tesaro-inc-tsro-to-sell/1590028.html.
In other news, SVP Martin H. Jr. Huber sold 190 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $136.26, for a total value of $25,889.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Mary Lynne Hedley sold 3,927 shares of the stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $177.61, for a total transaction of $697,474.47. Following the completion of the sale, the chief operating officer now directly owns 10,000 shares of the company’s stock, valued at approximately $1,776,100. The disclosure for this sale can be found here. In the last three months, insiders sold 15,793 shares of company stock valued at $2,801,638. Corporate insiders own 40.50% of the company’s stock.
Several hedge funds have recently bought and sold shares of TSRO. Capital Analysts LLC purchased a new stake in TESARO during the fourth quarter valued at $134,000. Massmutual Trust Co. FSB ADV purchased a new stake in TESARO during the fourth quarter valued at $134,000. Citizens Financial Group Inc RI purchased a new stake in TESARO during the third quarter valued at $154,000. CenturyLink Investment Management Co purchased a new stake in TESARO during the third quarter valued at $172,000. Finally, Pacer Advisors Inc. bought a new position in shares of TESARO during the third quarter valued at approximately $216,000. 98.48% of the stock is owned by institutional investors and hedge funds.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.